Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review

References

• Gutiérrez-Rojas L, Porras-Segovia A, Dunne H, et al. Prevalence and correlates of major depressive disorder: a systematic review. Braz J Psychiatry. 2020;42(6):657–672.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th. APA. 2013. DSM–5. https://www.psychiatry.org/psychiatrists/practice/dsm
   Google Scholar
• Bora E, Harrison BJ, Yücel M, et al. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017–2026.
   PubMed Web of Science ®Google Scholar
• Etkin A, Patenaude B, Song YJ, et al. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial. Neuropsychopharmacology. 2015;40(6):1332–1342.
   PubMed Web of Science ®Google Scholar
• Jaeger J, Berns S, Uzelac S, et al. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39–48.
   PubMed Web of Science ®Google Scholar
• Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513–520.
   PubMed Web of Science ®Google Scholar
• Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000–1006.
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet. 2013;382(9904):1575–1586.
   PubMed Web of Science ®Google Scholar
• Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58(1):19–36.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(Suppl 13):23–29.
   PubMed Web of Science ®Google Scholar
• David DJ, Gourion D. Antidépresseurs et tolérance: déterminants et prise en charge des principaux effets indésirables[Antidepressant and tolerance: determinants and management of major side effects]. Encephale. 2016;42(6):553–561.
   PubMed Web of Science ®Google Scholar
• Wille SM, Cooreman SG, Neels HM, et al. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci. 2008;45(1):25–89.
   PubMed Web of Science ®Google Scholar
• Bauer M, Pfennig A, Severus E, et al. Task force on unipolar depressive disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–385.
   PubMed Web of Science ®Google Scholar
• Artigas F, Bortolozzi A, Celada P. Can we increase speed and efficacy of antidepressant treatments? Part I: general aspects and monoamine-based strategies. Eur Neuropsychopharmacol. 2018;28(4):445–456.
   PubMed Web of Science ®Google Scholar
• Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–288.
   PubMed Web of Science ®Google Scholar
• Whiskey E, Taylor D. A review of the adverse effects and safety of noradrenergic antidepressants. J Psychopharmacol. 2013;27(8):732–739.
   PubMed Web of Science ®Google Scholar
• Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. Can J Psychiatry. 2016;61(1):29–43.
   PubMed Web of Science ®Google Scholar
• Wichniak A, Wierzbicka A, Walęcka M, et al. Effects of antidepressants on sleep. Curr Psychiatry Rep. 2017;19(9):63.
   PubMed Web of Science ®Google Scholar
• Song HR, Kwon YJ, Woo YS, et al. Effects of mirtazapine on patients undergoing naturalistic diabetes treatment: a follow-up study extended from 6 to 12 months. J Clin Psychopharmacol. 2015;35(6):730–731.
   PubMed Web of Science ®Google Scholar
• Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:1297–1307.
   PubMed Web of Science ®Google Scholar
• Citrome L. Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2016;196:225–233.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 391(10128): 1357–1366. 2018.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Trintellix® (formerly Brintellix®) Medication guide (revised 07/2019). 2020. [cited 2021 Dec 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204447s018lbl.pdf
   Google Scholar
• Chen G, Højer AM, Areberg J, et al. Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018;57(6):673–686.
   PubMed Web of Science ®Google Scholar
• Chen G, Nomikos GG, Affinito J, et al. Effects of intrinsic factors on the clinical pharmacokinetics of vortioxetine. Clin Pharmacol Drug Dev. 2018;7(8):880–888.
   PubMed Web of Science ®Google Scholar
• Chen G, Nomikos GG, Affinito J, et al. Lack of effect of vortioxetine on the pharmacokinetics and pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet. 2016;55(9):1115‐1127.
   Web of Science ®Google Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
   PubMed Web of Science ®Google Scholar
• Nackenoff AG, Simmler LD, Baganz NL, et al. Serotonin transporter-independent actions of the antidepressant vortioxetine as revealed using the SERT Met172 mouse. ACS Chem Neurosci. 2017;8(5):1092–1100.
   PubMed Web of Science ®Google Scholar
• Li Y, Raaby KF, Sánchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520–528.
   PubMed Web of Science ®Google Scholar
• Hlavacova N, Li Y, Pehrson A, et al. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:332–338.
   PubMed Web of Science ®Google Scholar
• Riga MS, Sánchez C, Celada P, et al. Involvement of 5-HT3 receptors in the action of vortioxetine in rat brain: focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology. 2016;108:73–81.
   PubMed Web of Science ®Google Scholar
• Du Jardin KG, Müller HK, Sanchez C, et al. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. Eur J Pharmacol. 2016;786:29–35.
   PubMed Web of Science ®Google Scholar
• Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45(9):1085–1098.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Voleti B, Hajszan T, et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat Med. 2012;18(9):1413–1417.
   PubMed Web of Science ®Google Scholar
• Chen F, Du Jardin KG, Waller JA, et al. Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. Eur Neuropsychopharmacol. 2016;26(2):234–245.
   PubMed Web of Science ®Google Scholar
• Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research. Front Psychiatry. 2019;10:771.
   PubMed Web of Science ®Google Scholar
• Leiser SC, Pehrson AL, Robichaud PJ, et al. Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine–a quantitative EEG study in rats. Br J Pharmacol. 2014;171(18):4255–4272.
   PubMed Web of Science ®Google Scholar
• Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120(11):3779–3787.
   PubMed Web of Science ®Google Scholar
• Zuena AR, Maftei D, Alemà GS, et al. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain. 2018;14:1744806918808987.
   Web of Science ®Google Scholar
• Talmon M, Rossi S, Pastore A, et al. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018;175(1):113‐124.
   PubMed Web of Science ®Google Scholar
• Köhler CA, Freitas TH, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017;135(5):373–387.
   PubMed Web of Science ®Google Scholar
• Tomaz VS, Chaves Filho AJM, Cordeiro RC, et al. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord. 2020;268:188–200.
   PubMed Web of Science ®Google Scholar
• Fourrier C, Sampson E, Mills NT, et al. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials. 2018;19(1):447.
   PubMedGoogle Scholar
• Talmon M, Chaudhari RD, Suryavanshi H, et al. Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes. Bioorg Med Chem. 2020;28(23):115760.
   PubMed Web of Science ®Google Scholar
• Salagre E, Grande I, Solé B, et al. Vortioxetina: una nueva alternativa en el trastorno depresivo mayor.[Vortioxetine: a new alternative for the treatment of major depressive disorder]. Rev. Psiquiatr Salud Ment (Barc.). 2018;11(1):48–59.
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, et al., A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 26(6): 979–993. 2016.
   PubMed Web of Science ®Google Scholar
• Furukawa TA, Cipriani A, Cowen PJ, et al. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6(7):601–609.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: a randomized, double-blinded, exploratory study with vortioxetine. J Affect Disord. 2019;250:35‐42.
   Web of Science ®Google Scholar
• Lee RS, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140(2):113–124.
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials. Int J Neuropsychopharmacol. 2015;19(2):yv082.
   Web of Science ®Google Scholar
• Baune BT, Brignone M, Larsen KG. A network meta-analysis comparing effects of various antidepressant classes on the digit symbol substitution Test (DSST) as a measure of cognitive dysfunction in patients with major depressive disorder. Int J Neuropsychopharmacol. 2018;21(2):97–107.
   PubMed Web of Science ®Google Scholar
• Harrison JE, Lophaven S, Olsen CK. Which Cognitive Domains are Improved by Treatment with Vortioxetine? Int J Neuropsychopharmacol. 2016 May 26;19(10):yw054.
   Web of Science ®Google Scholar
• Jacobson W, Zhong W, Nomikos GG, et al. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. Curr Med Res Opin. 2020;36(1):117–124.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, et al., The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 19(10): yw055. 2016.
   Web of Science ®Google Scholar
• Chokka P, Bougie J, Rampakakis E, et al. Assessment in work productivity and the relationship with cognitive symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. 2019;24(3):338–347.
   PubMed Web of Science ®Google Scholar
• Chokka P, Bougie J, Proulx J, et al. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr. 2019;24(6):616–627.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Florea I, Tonnoir B, et al. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78(1):115–121.
   PubMed Web of Science ®Google Scholar
• Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: a short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord. 2018;227:803–809.
   PubMed Web of Science ®Google Scholar
• Nissen TD, Laursen B, Viardot G, et al. Effects of vortioxetine and escitalopram on electroencephalographic recordings - a randomized, crossover trial in healthy males. Neuroscience. 2020;424:172‐181.
   PubMed Web of Science ®Google Scholar
• Smith J, Browning M, Conen S, et al. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry. 2018;23(5):1127–1133.
   PubMed Web of Science ®Google Scholar
• Orgeta V, Tabet N, Nilforooshan R, et al. efficacy of antidepressants for depression in Alzheimer’s Disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58(3):725–733.
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Stevens A, Waring JD, et al. Augmenting computerized cognitive training with vortioxetine for age-related cognitive decline: a randomized controlled trial. Am J Psychiatry. 2020;177(6):548–555.
   Web of Science ®Google Scholar
• Cumbo E, Cumbo S, Torregrossa S, et al. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer’s Disease Patients with Depressive Symptoms: a 12 Month, Open-Label, Observational Study. J Prev Alzheimers Dis. 2019;6(3):192–197.
   PubMed Web of Science ®Google Scholar
• Paolucci S. Advances in antidepressants for treating post-stroke depression. Expert Opin Pharmacother. 2017;18(10):1011‐1017.
   PubMed Web of Science ®Google Scholar
• Strelnikova IA, Svetkina AA, YuD M, et al. Experience with vortioxetine in the treatment of post-stroke depression. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology. Neuropsychiatry, Psychosomatics. 2020;12(1):45–49.
   PubMedGoogle Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 61(9): 540–560. 2016.
   PubMed Web of Science ®Google Scholar
• Cao B, Park C, Subramaniapillai M, et al. The efficacy of vortioxetine on anhedonia in patients with major depressive disorder. Front Psychiatry. 2019;10:17.
   PubMed Web of Science ®Google Scholar
• Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007;99(1–3):83–89.
   PubMed Web of Science ®Google Scholar
• Subramaniapillai M, Mansur RB, Zuckerman H, et al. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry. 2019;94:152113.
   PubMed Web of Science ®Google Scholar
• Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol. 2002;5(2):147–151.
   PubMed Web of Science ®Google Scholar
• Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study. Br J Psychiatry. 2009;195(3):211–217.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Florea I, Loft H, et al. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021;283:472–479.
   PubMed Web of Science ®Google Scholar
• Cronquist MC, Florea I, Lindsten A, et al. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol. 2018;32(10):1086‐1097.
   Web of Science ®Google Scholar
• Jaracz J, Gattner K, Jaracz K, et al. Unexplained painful physical symptoms in patients with major depressive disorder: prevalence, pathophysiology and management. CNS Drugs. 2016;30(4):293–304.
   PubMed Web of Science ®Google Scholar
• Cao B, Park C, Rosenblat JD, et al. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: an open-label clinical trial. J Psychopharmacol. 2019;33(11):1388–1394.
   PubMed Web of Science ®Google Scholar
• Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. Br J Clin Pharmacol. 2019;85(1):240–244.
   PubMed Web of Science ®Google Scholar
• Doghramji K, Jangro WC. Adverse effects of psychotropic medications on sleep. Psychiatr Clin North Am. 2016;39(3):487–502.
   PubMed Web of Science ®Google Scholar
• Leiser SC, Iglesias-Bregna D, Westrich L, et al. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol. 2015;29(10):1092–1105.
   PubMed Web of Science ®Google Scholar
• Wilson S, Højer AM, Buchberg J, et al. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol. 2015;29(10):1085‐1091.
   Web of Science ®Google Scholar
• Bonaventure P, Kelly L, Aluisio L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007;321(2):690–698.
   PubMed Web of Science ®Google Scholar
• Shelton J, Bonaventure P, Li X, et al. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology. 2009;56(2):448–454.
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry. 2007;164(7):1029–1034.
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry. 2006;163(1):41–47.
   PubMed Web of Science ®Google Scholar
• Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160(4):790–792.
   PubMed Web of Science ®Google Scholar
• Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ. 2005;330(7488):385.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Affinito J, Reines EH, et al. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. CNS Spectr. 2019;14:1–11.
   Google Scholar
• Baldwin DS, Florea I, Jacobsen PL, et al. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. J Affect Disord. 2016;206:140–150.
   PubMed Web of Science ®Google Scholar
• Blanco C, Nissenson K, Liebowitz MR. Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment. Curr Psychiatry Rep. 2001;3(4):273–280.
   PubMedGoogle Scholar
• Liebowitz MR, Careri J, Blatt K, et al. Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder. Depress Anxiety. 2017;34(12):1164–1172.
   PubMed Web of Science ®Google Scholar
• Cronquist MC, Florea I, Loft H, et al. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord. 2020;263:258–266.
   PubMed Web of Science ®Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–816.
   PubMed Web of Science ®Google Scholar
• Di Nicola M, Pepe M, Panaccione I, et al. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis. CNS Spectr 2020 1–9 https://doi.org/10.1017/S109285292000173X
   Google Scholar
• Oslin DW, Datto CJ, Kallan MJ, et al. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc. 2002;50(5):823–828.
   PubMed Web of Science ®Google Scholar
• Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141(2–3):103–115.
   PubMed Web of Science ®Google Scholar
• Nomikos GG, Tomori D, Zhong W, et al. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr. 2017;22(4):348‐362.
   PubMed Web of Science ®Google Scholar
• Agüera-Ortiz LF. Tratamiento actual de la depresión en el anciano: un foco en la vortioxetina.[Current treatment of depression in the elderly: a focus on vortioxetine]. Psicogeriatria. 2020;10(Supl 1):S1–S9.
   Google Scholar
• Freeman MP, Cheng LJ, Moustafa D, et al. Vortioxetine for major depressive disorder, vasomotor, and cognitive symptoms associated with the menopausal transition. Ann Clin Psychiatry. 2017;29(4):249–257.
   PubMed Web of Science ®Google Scholar
• Callegari C, Ielmini M, Caselli I, et al. Paroxetine versus vortioxetine for depressive symptoms in postmenopausal transition: a preliminary study. Psychopharmacol Bull. 2019;49(1):28–43.
   PubMedGoogle Scholar
• Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370(9590):851–858.
   PubMed Web of Science ®Google Scholar
• Fiore V, Marci M, Poggi A, et al. The association between diabetes and depression: a very disabling condition. Endocrine. 2015;48(1):14–24.
   PubMed Web of Science ®Google Scholar
• Roopan S, Larsen ER. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr. 2017;29(3):127–139.
   PubMed Web of Science ®Google Scholar
• Tovilla-Zárate CA, Pérez-Mandujano A, Ramírez-González IR, et al. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Ann Transl Med. 2019;7(22):656.
   PubMed Web of Science ®Google Scholar
• Lee MD, Kennett GA, Dourish CT, et al. 5-HT1B receptors modulate components of satiety in the rat: behavioural and pharmacological analyses of the selective serotonin1B agonist CP-94,253. Psychopharmacology (Berl). 2002;164(1):49–60.
   PubMed Web of Science ®Google Scholar
• Nonogaki K, Kaji T. Pharmacological stimulation of serotonin 5-HT1B receptors enhances increases in plasma active glucagon-like peptide-1 levels induced by dipeptidyl peptidase-4 inhibition independently of feeding in mice. Diabetes Metab. 2015;41(5):425–428.
   PubMed Web of Science ®Google Scholar
• Russo M, Carrarini C, Dono F, et al. Vortioxetine treatment of depression in Parkinson’s disease[abstract]. Mov Disord. 2019; 34(suppl 2). [cited 2021 Dec 20]. Available from https://www.mdsabstracts.org/abstract/vortioxetine-treatment-of-depression-in-parkinsons-disease/
   PubMedGoogle Scholar
• Postuma RB, Gagnon JF, Tuineaig M, et al. Antidepressants and REM sleep behavior disorder: isolated side effect or neurodegenerative signal? Sleep. 2013;36(11):1579–1585.
   PubMed Web of Science ®Google Scholar
• Aurora RN, Zak RS, Maganti RK, et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010;6(1):85–95.
   PubMed Web of Science ®Google Scholar
• Adamo D, Pecoraro G, Coppola N, et al. Vortioxetine versus other antidepressants in the treatment of burning mouth syndrome: an open-label randomized trial. Oral Dis. 2020;27(4):1022–1041.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nielsen RZ, Poulsen LH, et al. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–482.
   PubMed Web of Science ®Google Scholar
• Thase ME, Danchenko N, Brignone M, et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(8):773‐781.
   PubMed Web of Science ®Google Scholar
• Brignone M, Diamand F, Painchault C, et al. Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. Curr Med Res Opin. 2016;32(2):351–366.
   PubMed Web of Science ®Google Scholar
• Tegin C, Tegin G, El-Mallakh RS. Effective vortioxetine dose varies with extent of antidepressant use across countries. Psychopharmacol Bull. 2018;48(1):26‐39.
   PubMedGoogle Scholar
• Garcia-Toro M, Medina E, Galan JL, et al. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry. 2012;12(1):143.
   PubMedGoogle Scholar
• Goldberg JF, Freeman MP, Balon R, et al. The American society of clinical psychopharmacology survey of psychopharmacologists’ practice patterns for the treatment of mood disorders. Depress Anxiety. 2015;32(8):605–613.
   PubMed Web of Science ®Google Scholar
• Florea I, Loft H, Danchenko N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622.
   PubMed Web of Science ®Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, et al. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Cronquist MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787–794.
   PubMed Web of Science ®Google Scholar
• Soini E, Hallinen T, Brignone M, et al. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):293–302.
   PubMed Web of Science ®Google Scholar
• Young AH, Evitt L, Brignone M, et al. Cost-utility evaluation of vortioxetine in patients with major depressive disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. J Affect Disord. 2017;218:291–298.
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266.
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Palo WA, et al. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectr. 2016;21(5):367–378.
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Zhong W, Nomikos G, et al. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: a randomized, controlled trial. J Sex Med. 2019;16(10):1638–1649.
   PubMed Web of Science ®Google Scholar
• Montejo AL, Prieto N, de Alarcón R, et al. Management strategies for antidepressant-related sexual dysfunction: a clinical approach. J Clin Med. 2019;8(10):1640.
   Web of Science ®Google Scholar
• Jacobsen PL, Mahableshwarkar AR, Chen Y, et al. Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing ssri-induced sexual dysfunction. J Sex Med. 2015;12(10):2036–2048.
   PubMed Web of Science ®Google Scholar
• Olivier JDA, Olivier B. Antidepressants and sexual dysfunctions: a translational perspective. Curr Sex Health Rep. 2019;11(3):156–166.
   Google Scholar
• Li Y, Pehrson AL, Oosting RS, et al. A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: possible roles of direct receptor modulation. Neuropharmacology. 2017;121:89–99.
   PubMed Web of Science ®Google Scholar
• Jacobsen PL, Harper L, Chrones L, et al. Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2015;30(5):255–264.
   PubMed Web of Science ®Google Scholar
• Zheng J, Wang Z, Li E. The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis. Afr Health Sci. 2019;19(1):1716–1726.
   PubMed Web of Science ®Google Scholar
• Behzadifar M, Dehghan H, Saki K, et al. Evaluation efficacy and safety of Vortioxetine 20 mg/d versus placebo for treatment major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. Pharmacology & Pharmacy. 2015;6(4):221.
   Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252.
   PubMed Web of Science ®Google Scholar
• Coupland NJ, Bailey JE, Potokar JP, et al. 5-HT3 receptors, nausea, and serotonin reuptake inhibition. J Clin Psychopharmacol. 1997;17(2):142–143.
   PubMed Web of Science ®Google Scholar
• Ladefoged LK, Munro L, Pedersen AJ, et al. Modeling and mutational analysis of the binding mode for the multimodal antidepressant drug vortioxetine to the human 5-HT3A receptor. Mol Pharmacol. 2018;94(6):1421–1434.
   PubMed Web of Science ®Google Scholar
• Crapanzano C, Politano A, Amendola C, et al. Vortioxetine-induced nausea and its treatment: a case report. Archives of Clinical Psychiatry (São Paulo). 2021;47(5):160–161.
   Google Scholar
• Parker LA, Rock EM, Limebeer CL. Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol. 2011;163(7):1411–1422.
   PubMed Web of Science ®Google Scholar
• Johnston KD, Lu Z, Rudd JA. Looking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting. Eur J Pharmacol. 2014;722:13–25.
   PubMed Web of Science ®Google Scholar
• Fava GA, Benasi G, Lucente M, et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom. 2018;87(4):195–203.
   PubMed Web of Science ®Google Scholar
• Chen G, Lee R, Højer AM, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–736.
   PubMed Web of Science ®Google Scholar
• Schäfer W, Princk C, Kollhorst B, et al. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case-control study. Drug Saf. 2019;42(9):1081–1089.
   PubMed Web of Science ®Google Scholar
• Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol. 2015;55(6):671–679.
   PubMed Web of Science ®Google Scholar
• Me IO, Gaete GL. Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence. Rev Med Chil. 2016;144(10):1326–1335.
   PubMed Web of Science ®Google Scholar